fda glp-1 compounding warning letters october 2025 Sends to More Than 50 Compounders and Manufacturers FDA warns against compounded GLP-1

doi:10.1016/j.hepres.2005.12.005

The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood glucose levels without causing excessive hypoglycaemia Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake Most GLP-1 receptor agonists are administered via subcutaneous injection, with dosing frequencies ranging from once daily to once weekly depending on the specific formulation

It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication

K.LuevanoJ